Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: Continuous vs Bolus Neuromuscular Blockade in ARDS
NCT07567768Phase 2Not yet recruiting
- Sponsor
- University of Calgary
- Start
- Jan 2027
- Primary completion
- Jan 2027
01
Overview
Phase 2, randomised trial in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by University of Calgary. Primary endpoints: Recruitment rate among eligible patients at 48 hours, Protocol adherence rate at 28 days and 2 more. Planned start Jan 2027; status: not yet recruiting.
02
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07567768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567768.